Comparison

Recombinant Human DLL4 Protein (Fc Tag)

Item no. PKSH031806-500ug
Manufacturer Elabscience
Amount 500 ug
Quantity options 100 ug 50 ug 500 ug
Category
Type Proteins
Format Lyophilized Powder
Applications ELISA, Cell Culture
Specific against Human (Homo sapiens)
Host HEK293 cells
Conjugate/Tag C-hFc
Purity > 95 % as determined by reducing SDS-PAGE.
Sequence Met 1-Pro 524
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias DLL4, Delta-like protein 4, Delta4, Drosophila Delta homolog 4
Shipping Condition Cool pack
Available
Manufacturer - Category
Recombinant Proteins / Others
Manufacturer - Conjugate / Tag
C-hFc
Shipping Temperature
This product is provided as lyophilized powder which is shipped with ice packs.
Storage Conditions
Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Calculated Molecular Weight
81.0 kDa
Observed Molecular Weight
100-110 kDa
Manufacturer - Research Areas
Cell biology, Neuroscience, epigenetics and nuclear signal
Background
Delta-like protein 4 (DLL4; Delta4); a type I membrane-bound Notch ligand; is one of five known Notch ligands in mammals and interacts predominantly with Notch 1; which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth; forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore; the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions; such as cancer; DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis; but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies; blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density; yet causes marked growth inhibition due to functionally defective vasculature. Thus; DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method.
Reconstitution
Please refer to the printed manual for detailed information.
Formulation
Lyophilized from sterile PBS, pH 7.4
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Activity
1. Immobilized human DLL4 at 10 μg/mL (100 μL/well) can bind biotinylated mouse NOTCH1-his. The EC50 of biotinylated mouse NOTCH1-his is 40 ng/mL. 2. Measured by the ability of the immobilized protein to enhance BMP2-induced alkaline phosphatase activity in C3H10T1/2 mouse embryonic fibroblast cells. The ED50 for this effect is typically 1-8 µg/mL in the presence of 500 ng/mL recombinant human BMP2.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?